Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth

Journal of Medicinal Chemistry

Volumn 57, Issue 4, 2014, Pages 1355-1367

  Pelà, Michela ^a   Saxena, Puneet ^b   Luciani, Rosaria ^b   Santucci, Matteo ^b   Ferrari, Stefania ^b   Marverti, Gaetano ^b   Marraccini, Chiara ^b   Martello, Andrea ^b   Pirondi, Silvia ^b   Genovese, Filippo ^b   Salvadori, Severo ^a,c   D'Arca, Domenico ^b   Ponterini, Glauco ^b   Costi, Maria Paola ^b   Guerrini, Remo ^a,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Laboratorio per le Tecnologie delle Terapie Avanzate   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DIHYDROFOLATE REDUCTASE; FLUOROURACIL; PEPTIDE LR; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CIRCULAR DICHROISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; OVARY CANCER;

CELL DIVISION; CELL LINE, TUMOR; CIRCULAR DICHROISM; CRYSTALLOGRAPHY; FEMALE; HUMANS; MOLECULAR DYNAMICS SIMULATION; OVARIAN NEOPLASMS; PEPTIDES; POLYMERASE CHAIN REACTION; PROTEIN CONFORMATION; THYMIDYLATE SYNTHASE;

EID: 84896882170     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401574p     Document Type: Article

References (44)

1. Metzger, R.; Leichman, C. G.; Danenberg, K. D.; Danenberg, P. V.; Lenz, H. J.; Hayashi, K.; Groshen, S.; Salonga, D.; Cohen, H.; Laine, L.; Crookes, P.; Silberman, H.; Baranda, J.; Konda, B.; Leichman, L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J. Clin. Oncol. 1998, 16, 309-316
2. Garg, D.; Beribisky, A. V.; Ponterini, G.; Ligabue, A.; Marverti, G.; Martello, A.; Costi, M. P.; Sattler, M.; Wade, R. C. Translational repression of thymidylate synthase by targeting its mRNA Nucleic Acids Res. 2013, 41, 4159-4170
3. Chu, E.; Allegra, C. J. The role of thymidylate synthase as an RNA binding protein Bioessays 1996, 18, 191-198
4. Chu, E.; Koeller, D. M.; Casey, J. L.; Drake, J. C.; Chabner, B. A.; Elwood, P. C.; Zinn, S.; Allegra, C. J. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8977-8981
5. Chu, E.; Voeller, D.; Koeller, D. M.; Drake, J. C.; Takimoto, C. H.; Maley, G. F.; Maley, F.; Allegra, C. J. Identification of an RNA binding site for human thymidylate synthase Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 517-521
6. Liu, J.; Schmitz, J. C.; Lin, X.; Tai, N.; Yan, W.; Farrell, M.; Bailly, M.; Chen, T.; Chu, E. Thymidylate synthase as a translational regulator of cellular gene expression Biochim. Biophys. Acta 2002, 1587, 174-182
7. Ju, J.; Pedersen-Lane, J.; Maley, F.; Chu, E. Regulation of p53 expression by thymidylate synthase Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 3769-3774
8. Ozasa, H.; Oguri, T.; Uemura, T.; Miyazaki, M.; Maeno, K.; Sato, S.; Ueda, R. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer Cancer Sci. 2010, 101, 161-166
9. Chu, E.; Callender, M. A.; Farrell, M. P.; Schmitz, J. C. Thymidylate synthase inhibitors as anticancer agents: From bench to bedside Cancer Chemother. Pharmacol. 2003, 52 (Suppl 1) 80-89
10. Berger, S. H.; Berger, F. G.; Lebioda, L. Effects of ligand binding and conformational switching on intracellular stability of human thymidylate synthase Biochim. Biophys. Acta 2004, 1696, 15-22
11. Kitchens, M. E.; Forsthoefel, A. M.; Rafique, Z.; Spencer, H. T.; Berger, F. G. Ligand mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation J. Biol. Chem. 1999, 274, 12544-12547
12. Bast, R. C., Jr.; Hennessy, B.; Mills, G. B. The biology of ovarian cancer: New opportunities for translation Nat. Rev. Cancer 2009, 9, 415-428
13. Scanlon, K. J.; Kashani-Sabet, M. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 650-653
14. Marverti, G.; Ligabue, A.; Paglietti, G.; Corona, P.; Piras, S.; Vitale, G.; Guerrieri, D.; Luciani, R.; Costi, M. P.; Frassineti, C.; Moruzzi, M. S. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells Eur. J. Pharmacol. 2009, 615, 17-26
15. Cardinale, D.; Guaitoli, G.; Tondi, D.; Luciani, R.; Henrich, S.; Salo-Ahen, O. M.; Ferrari, S.; Marverti, G.; Guerrieri, D.; Ligabue, A.; Frassineti, C.; Pozzi, C.; Mangani, S.; Fessas, D.; Guerrini, R.; Ponterini, G.; Wade, R. C.; Costi, M. P. Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase Proc. Natl. Acad. Sci. U.S.A. 2011, 108, E542-E549
16. Phan, J.; Koli, S.; Minor, W.; Dunlap, R. B.; Berger, S. H.; Lebioda, L. Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antidotal drug Biochemistry 2001, 40, 1897-1902
17. Phan, J.; Steadman, D. J.; Koli, S.; Ding, W. C.; Minor, W.; Dunlap, R. B.; Berger, S. H.; Lebioda, L. Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors J. Biol. Chem. 2001, 276, 14170-14177
18. Hruby, V. J.; Balse, P. M. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads Curr. Med. Chem. 2000, 7, 945-970
19. Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy Angew. Chem., Int. Ed. Engl. 1997, 36, 1374-1389
20. Chang, Y. P.; Chu, Y. H. Using surface plasmon resonance to directly determine binding affinities of combinatorially selected cyclopeptides and their linear analogs to a streptavidin chip Anal. Biochem. 2005, 340, 74-79
21. Dathe, M.; Nikolenko, H.; Klose, J.; Bienert, M. Cyclization increases the antimicrobial activity and selectivity of arginine- and tryptophan- containing hexapeptides Biochemistry 2004, 43, 9140-9150
22. Dumez, E.; Snaith, J. S.; Jackson, R. F.; McElroy, A. B.; Overington, J.; Wythes, M. J.; Withka, J. M.; McLellan, T. J. Synthesis of macrocyclic, potential protease inhibitors, using a generic scaffold J. Org. Chem. 2002, 67, 4882-4892
23. Kang, J. H.; Kim, S. Y.; Lee, L.; Marquez, V. E.; Lewin, N. E.; Pearce, L. V.; Blumberg, P. M. Macrocyclic diacylglycerol-bis-lactones as conformationally constrained analogues of diacylglycerol-lactones. Interactions with protein kinase C J. Med. Chem. 2004, 47, 4000-4007
24. Khan, A. R.; Parrish, J. C.; Fraser, M. E.; Smith, W. W.; Bartlett, P. A.; James, M. N. Lowering the entropic barrier for binding conformationally flexible inhibitors to enzymes Biochemistry 1998, 37, 16839-16845
25. Nam, N. H.; Ye, G.; Sun, G.; Parang, K. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding J. Med. Chem. 2004, 47, 3131-3141
26. Woody, R. W. Circular dichroism Methods Enzymol. 1995, 246, 34-71
27. Vass, E.; Holly, S.; Majer, Z. S.; Samu, J.; Laczkò, I.; Hollòsi, M. FTIR and CD spectroscopic detection of H-bonded folded J. Mol. Struct. 1997, 408/409, 47-56
28. Smith, J. A.; Pease, L. G. Reverse turns in peptides and proteins CRC Crit. Rev. Biochem. 1980, 8, 315-399
29. Sreerama, N.; Manning, M. C.; Powers, M. E.; Zhang, J.-X.; Goldenberg, D. P.; Woody, R. W. Tyrosine, phenylalanine, and disulfide contributions to the circular dichroism of proteins: Circular dichroism spectra of wild-type and mutant bovine pancreatic trypsin inhibitor Biochemistry 1999, 38, 10814-10822
30. Chou, K.-C. Prediction of tight turns and their types in proteins Anal. Biochem. 2000, 286, 1-16
31. Kabsch, W.; Scander, C. Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features Biopolymers 1983, 22, 2577-2637
32. Benoiton, N. L. Chemistry of Peptide Synthesis; Taylor& Francis: London, 2005; pp 125-154.
33. Solé, N. A.; Barany, G. Optimization of solid-phase synthesis of [Ala8]-dynorphin J. Org. Chem. 1992, 57, 5399-5403
34. Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation J. Chem. Theor. Comput. 2008, 4, 435-447
35. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: an N-log(N) method for Ewald sums in large systems J. Chem. Phys. 1993, 98, 10089-10092
36. Humprey, W.; Dalke, A.; Schulman, K. VMD-visual molecular dynamics J. Mol. Graphics 1996, 14, 33-38
37. DiSaia, P. J.; Sinkovics, J. G.; Rutledge, F. N.; Smith, J. P. Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors Am. J. Obstet. Gynecol. 1972, 114, 979-989
38. Andrews, P. A.; Murphy, M. P.; Howell, S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion Cancer Res. 1985, 45, 6250-6253
39. Andrews, P. A.; Jones, J. A. Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA Cancer Commun. 1991, 3, 1-10
40. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the folic phenol reagent J. Biol. Chem. 1951, 193, 265-275
41. Kueng, W.; Siber, E.; Eppenberger, U. Quantification of cells cultured on 96-well plates Anal. Biochem. 1989, 182, 16-19
42. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 1970, 227, 680-685
43. Arocho, A.; Chen, B.; Ladanyl, M.; Pan, Q. Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts Diagn. Mol. Pathol. 2006, 15, 56-61
44. van Triest, B.; Pinedo, H. M.; van Hensbergen, Y.; Smid, K.; Telleman, F.; Schoenmakers, P. S.; van der Wilt, C. L.; van Laar, J. A. M.; Noordhuis, P.; Jansen, G.; Peters, G. J. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 non selected colon cancer cell lines Clin. Cancer Res. 1999, 5, 643-654